Header Logo

Connection

LEO LUZNIK to Animals

Back to Details
This is a "connection" page, showing publications LEO LUZNIK has written about Animals.
LEO LUZNIK
Connection Strength
0.392
Animals
  1. PTCy and "The Story of the Three Bears". Bone Marrow Transplant. 2021 04; 56(4):765-766.
    View in: PubMed
    Score: 0.032
  2. Teaching a Young Dog New Tricks: Modifications to the Post-Transplantation Cyclophosphamide Haploidentical Transplantation Platform. Biol Blood Marrow Transplant. 2018 06; 24(6):1108-1110.
    View in: PubMed
    Score: 0.027
  3. Induction of Major Histocompatibility Complex-mismatched Mouse Lung Allograft Acceptance With Combined Donor Bone Marrow: Lung Transplant Using a 12-Hour Nonmyeloablative Conditioning Regimen. Transplantation. 2016 Dec; 100(12):e140-e146.
    View in: PubMed
    Score: 0.025
  4. Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice. Blood. 2014 Sep 25; 124(13):2131-41.
    View in: PubMed
    Score: 0.021
  5. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol. 2012 Dec; 39(6):683-93.
    View in: PubMed
    Score: 0.019
  6. High-dose cyclophosphamide for graft-versus-host disease prevention. Curr Opin Hematol. 2010 Nov; 17(6):493-9.
    View in: PubMed
    Score: 0.016
  7. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res. 2010 Jul; 47(1-3):65-77.
    View in: PubMed
    Score: 0.016
  8. STAT3 signaling in CD4+ T cells is critical for the pathogenesis of chronic sclerodermatous graft-versus-host disease in a murine model. J Immunol. 2010 Jan 15; 184(2):764-74.
    View in: PubMed
    Score: 0.015
  9. Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. Cancer Immunol Immunother. 2010 Jan; 59(1):137-48.
    View in: PubMed
    Score: 0.015
  10. Rapamycin promotes emergence of IL-10-secreting donor lymphocyte infusion-derived T cells without compromising their graft-versus-leukemia reactivity. Transplantation. 2007 Mar 15; 83(5):631-40.
    View in: PubMed
    Score: 0.012
  11. Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse. Blood. 2007 May 15; 109(10):4564-74.
    View in: PubMed
    Score: 0.012
  12. Host-derived Langerhans cells persist after MHC-matched allografting independent of donor T cells and critically influence the alloresponses mediated by donor lymphocyte infusions. J Immunol. 2006 Oct 01; 177(7):4414-25.
    View in: PubMed
    Score: 0.012
  13. Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity. Nat Cancer. 2024 Apr; 5(4):601-624.
    View in: PubMed
    Score: 0.010
  14. Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras. Blood. 2003 Feb 15; 101(4):1645-52.
    View in: PubMed
    Score: 0.009
  15. Efflux capacity and aldehyde dehydrogenase both contribute to CD8+ T-cell resistance to posttransplant cyclophosphamide. Blood Adv. 2022 09 13; 6(17):4994-5008.
    View in: PubMed
    Score: 0.009
  16. Donor T cell DNMT3a regulates alloreactivity in mouse models of hematopoietic stem cell transplantation. J Clin Invest. 2022 07 01; 132(13).
    View in: PubMed
    Score: 0.009
  17. BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes. Blood. 2022 05 12; 139(19):2983-2997.
    View in: PubMed
    Score: 0.009
  18. Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. Biol Blood Marrow Transplant. 2002; 8(3):131-8.
    View in: PubMed
    Score: 0.009
  19. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001 Dec 01; 98(12):3456-64.
    View in: PubMed
    Score: 0.009
  20. Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation. Front Immunol. 2020; 11:636.
    View in: PubMed
    Score: 0.008
  21. Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease. Blood. 2020 01 02; 135(1):28-40.
    View in: PubMed
    Score: 0.008
  22. Targeting PI3Kd function for amelioration of murine chronic graft-versus-host disease. Am J Transplant. 2019 06; 19(6):1820-1830.
    View in: PubMed
    Score: 0.007
  23. Short telomere syndromes cause a primary T cell immunodeficiency. J Clin Invest. 2018 12 03; 128(12):5222-5234.
    View in: PubMed
    Score: 0.007
  24. Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. Blood. 2019 01 03; 133(1):94-99.
    View in: PubMed
    Score: 0.007
  25. Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-? production. Blood. 2017 05 04; 129(18):2570-2580.
    View in: PubMed
    Score: 0.006
  26. Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia. Curr Drug Targets. 2017; 18(3):315-331.
    View in: PubMed
    Score: 0.006
  27. The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017 Feb; 23(2):211-234.
    View in: PubMed
    Score: 0.006
  28. Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner. Blood. 2016 08 18; 128(7):1013-7.
    View in: PubMed
    Score: 0.006
  29. Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood. 2016 04 28; 127(17):2144-54.
    View in: PubMed
    Score: 0.006
  30. Proceedings from the Second Haploidentical Stem Cell Transplantation Symposium-Haplo2014, San Francisco, California, December 4, 2014. Biol Blood Marrow Transplant. 2016 Apr; 22(4):594-604.
    View in: PubMed
    Score: 0.006
  31. Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment. Blood. 2016 Jan 21; 127(3):352-9.
    View in: PubMed
    Score: 0.006
  32. Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. Blood. 2015 Jun 25; 125(26):4085-94.
    View in: PubMed
    Score: 0.005
  33. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest. 2014 Nov; 124(11):4867-76.
    View in: PubMed
    Score: 0.005
  34. Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood. 2014 Jun 19; 123(25):3988-98.
    View in: PubMed
    Score: 0.005
  35. Sirolimus and post transplant Cy synergistically maintain mixed chimerism in a mismatched murine model. Bone Marrow Transplant. 2013 Oct; 48(10):1335-41.
    View in: PubMed
    Score: 0.005
  36. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood. 2012 Feb 09; 119(6):1570-80.
    View in: PubMed
    Score: 0.004
  37. The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells. Biol Blood Marrow Transplant. 2008 May; 14(5):499-509.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.